Independence Bank of Kentucky Raises Position in Vertex Pharmaceuticals Incorporated $VRTX

Posted by Brian Himes on Sep 2nd, 2026

Independence Bank of Kentucky boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 405.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,504 shares of the pharmaceutical company’s stock after buying an additional 3,613 shares during the quarter. Independence Bank of Kentucky’s holdings in Vertex Pharmaceuticals were worth $2,237,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Community Financial Services Group LLC bought a new position in Vertex Pharmaceuticals during the second quarter valued at about $26,000. Meeder Asset Management Inc. bought a new stake in Vertex Pharmaceuticals in the second quarter worth about $26,000. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $26,000. Elevation Wealth Partners LLC grew its position in shares of Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 28 shares during the period. Finally, Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $28,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.6%

NASDAQ:VRTX opened at $547.65 on Wednesday. The stock has a market cap of $138.99 billion, a P/E ratio of 31.88, a PEG ratio of 2.36 and a beta of 0.32. The business’s 50-day moving average price is $505.22 and its two-hundred day moving average price is $469.83. Vertex Pharmaceuticals Incorporated has a twelve month low of $374.17 and a twelve month high of $555.69.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.The company had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the company posted $4.52 earnings per share. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on VRTX shares. Stifel Nicolaus set a $500.00 target price on Vertex Pharmaceuticals in a research note on Tuesday, August 4th. TD Cowen lifted their price objective on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Truist Financial increased their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $569.52.

Read Our Latest Report on VRTX

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 4,062 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $450.00, for a total transaction of $1,827,900.00. Following the transaction, the chief marketing officer directly owned 16,953 shares of the company’s stock, valued at approximately $7,628,850. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at $5,709,519. This trade represents a 12.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 10,464 shares of company stock worth $4,959,397 over the last ninety days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.